The famous trial is an outlier. Beijing, 1997: the high-dose group's HbA1c dropped from 8.5% to 6.6% ¹, metformin-tier numbers that built the market. American and Dutch teams then ran the same test in Western diabetics and got nothing ^{2 3}. The Beijing diet was probably chromium-poor enough that supplementing fixed a deficit Western diets don't have.

What survives pooling is half a point. Across twenty-five trials, chromium lowers HbA1c by about half a point, only in the picolinate form, only above 200 μg/day ⁴. Metformin lowers it by a full point or more; the diabetes association doesn't recommend chromium at all ⁵.

Fat loss barely registers. Two independent meta-analyses pool half a kilo to one kilo over three to six months and call it "of doubtful clinical significance" ^{6 7}. That is below the noise of a normal week.

Cravings are the best felt signal, and it's thin. Craving-prone eaters reported less carbohydrate pull on 600 μg/day ^{8 9}, but both trials were industry-funded and unreproduced.

Two groups have any signal worth naming: type 2 diabetics already near goal on metformin, and people fighting strong carbohydrate cravings. A healthy adult on a varied diet has nothing to chase ¹⁰.

Treat it as a timed experiment. The failure mode isn't harm; it's paying twenty dollars a year for years for a capsule that quietly does nothing.

Be honest about the size of the win. A diabetes benefit shows up on a blood test at three months, invisible in how you feel; an easing craving is just a slightly easier 3pm. Both are real and both are small. Week twelve tells you which, if any, is yours.

The boring levers beat it. For blood sugar: weight loss, a walk after meals, and metformin ⁵. For fat: a calorie deficit and resistance training. For cravings: protein-forward meals and enough sleep. And a diet with any broccoli, whole grains or lean meat puts most people past the deficiency line anyway ¹⁰.